TA1 Research
Thymic Immunomodulatory Peptide
Research area: immune modulation research
Thymosin Alpha-1 (TA1) is a 28-amino acid acetylated peptide derived from prothymosin alpha, originally isolated from thymic tissue. It is one of the most studied immunomodulatory peptides, with pharmaceutical approvals in over 35 countries (marketed as Zadaxin) for specific immune-related applications.
Research Areas
T-Cell & Dendritic Cell Signaling
Research demonstrates TA1's activity in dendritic cell maturation and T-cell signaling pathways, particularly in stimulating T-helper cell differentiation, cytotoxic T-lymphocyte activation, and regulatory T-cell signaling.
Innate & Adaptive Immune Crossover
Studies examine how TA1 bridges innate and adaptive immune signaling pathways, including its effects on toll-like receptor (TLR) signaling, STAT1/3 pathway activation, and natural killer (NK) cell activity research.
Cytokine Modulation Research
Research investigates TA1's influence on cytokine production profiles including IL-2, IL-12, IFN-γ, and TNF-α signaling pathways in immune regulation and anti-inflammatory research contexts.
Viral & Infectious Disease Research
TA1 (Zadaxin) has been investigated in clinical settings across multiple countries for hepatitis B and hepatitis C treatment adjunct protocols. It is approved in some countries for these applications and as an adjuvant for influenza vaccination in elderly populations.
Approved in some countries (as Zadaxin) for hepatitis B/C adjunct therapy; investigational in others including the United States.
Research References
Discuss any health concerns with a licensed clinician before making health decisions.
Have questions about TA1?
Request a free consultation to ask questions and learn more about this research area.
Affiliate disclosure: I am an independent affiliate of The Longevity Consultants and may receive compensation if you request a consultation through me.
Request a free consultation